ChemDmart
Chemxpert Database
  • About
    • About
    • Leadership
    • Advisory Board
  • Products
    • ChemProtel - Product Intelligence
    • CompFolio - One Company Profile
    • CompGroupe - Group Company Profile
    • ChemScape - Data Landscape
    • ChemDmart - E-Market Place
    • DataIntel - Data Analytics/Trends
    • DataFeed - Data News/Feed
    • CompShow- Company Showcase
  • Sources
  • Subscription
  • User Guide
  • Contact
  • Book Demo Log In
  1. Home
  2. All News
  3. Sosei Heptares Acquires Idorsias Pharmaceuticals Business In Japan And Apac
News Feed
course image
  • Date not available
  • Admin
  • News Article

Sosei Heptares Acquires Idorsias Pharmaceuticals Business in Japan and APAC

Sosei Heptares has announced the acquisition of Idorsia's Pharmaceuticals business in Japan and the Asia-Pacific region, excluding China. This strategic move marks a significant step towards Sosei Heptares' transformation into a fully integrated biopharmaceutical powerhouse.

Sosei Group's acquisition of Idorsia Pharmaceuticals Japan and Idorsia Pharmaceuticals Korea is set to bring significant expertise in drug development and commercialisation to Sosei Heptares, along with a strong market presence in Japan and the Asia-Pacific (APAC) region, excluding China.

As part of the transaction, Sosei Heptares will obtain select rights for Japan and APAC (ex-China) to two GPCR-targeted products: PIVLAZ® and daridorexant, and exclusive opt-ins for the Phase 3 cenerimod and lucerastat programmes. 

Additionally, gain selected rights to up to five more clinical-stage programmes from Idorsia's development portfolio. This infusion of products and programmes will expand Sosei Heptares' drug pipeline and enhance its capabilities to develop and commercialise innovative medicines in the region.

The strategic transaction leverages three sources of innovation for Sosei Heptares: their own wholly owned discovery and early development pipeline, selected clinical candidates from Idorsia's pipeline, and in-licencing of clinical product candidates from third parties in Japan and APAC (ex-China).

One of the highlights of the acquisition is gaining rights to Idorsia's exciting pipeline of medicines, including the lead product PIVLAZ® (clazosentan), which has already been commercially launched and has seen rapid sales growth in Japan since its introduction in April 2022.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!

Categories

image
Product Related Updates
image
Certificates/Accreditation
image
Approval/Launch
image
Clinical Trial Update
image
Licensing/Partnering/Collaboration Deal
image
ODD/BTA/FTA Status
image
Merger/Acquisition
image
Warning/Recalls

Lifescience Intellipedia Pvt. Ltd.

C-89, Sector-65 Noida-U.P. 201301 (India)
Toll-Free: 18004190155
Phone: +91-120-6631301-361
Mobile: +91-9990237670
Email: info@lifescienceintellipedia.com
Email: sales@lifescienceintellipedia.com

USEFUL LINKS

  • Home
  • Privacy Policy
  • Terms & Conditions
  • Terms Of Use
  • Refund Policy
  • Blogs

OUR PRODUCTS

  • ChemProtel - Product Intelligence
  • CompFolio - One Company Profile
  • CompGroupe - Group Company Profile
  • ChemScape - Data Landscape
  • ChemDmart - E-Market Place
  • DataIntel - Data Analytics/Trends
  • DataFeed - Data News/Feed
  • CompShow- Company Showcase

LOCATION

© Copyright Lifescience Intellipedia Pvt. Ltd.. All Rights Reserved

Fill The Form